Flurbiprofen is a versatile nonsteroidal anti-inflammatory drug (NSAID) that has been in clinical use for several decades. This medication serves as an important therapeutic option for various inflammatory conditions and pain management. The following comprehensive overview explores the pharmacological properties, clinical applications, and safety considerations of this well-established NSAID.
Introduction
Flurbiprofen is a propionic acid derivative belonging to the NSAID family, possessing anti-inflammatory, analgesic, and antipyretic properties. It was developed by the research division of Boots UK during the 1960s, during the same period that saw the discovery of other important NSAIDs including ibuprofen, diclofenac, naproxen, ketoprofen, and sulindac.
First patented in 1964, flurbiprofen received medical approval in 1987 and was subsequently approved by the FDA in 1988, with generic versions becoming available from 1994 onward. Structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, flurbiprofen has established itself as an effective treatment option for various inflammatory conditions.
Chemical Structure
Flurbiprofen has the chemical formula C₁₅H₁₃FO₂ with an average molecular weight of 244.2609. Its IUPAC name is 2-(3-fluoro-4-phenylphenyl)propanoic acid, though it’s also known by several synonyms including 2-fluoro-α-methyl-4-biphenylacetic acid.
The compound features a biphenyl structure with a fluorine atom at the ortho position of one phenyl ring and a propanoic acid side chain. Commercially available flurbiprofen is a racemic mixture of (+)S- and (-)R-enantiomers, with the S-enantiomer possessing most of the anti-inflammatory activity, while both enantiomers contribute to its analgesic properties. The compound has a melting point of 117°C (243°F).
Flurbiprofen-Based Medicines
Flurbiprofen is available in multiple formulations across global markets. Below are eight commonly encountered flurbiprofen-based medications:
- Ansaid – Oral tablets for systemic use in treating arthritis and pain
- Ocufen – Ophthalmic solution used pre-operatively to prevent miosis
- Froben – Tablets for systemic anti-inflammatory and analgesic effects
- Strefen – Available as lozenges and oromucosal spray for sore throat relief
- Arflur – Tablets in various strengths (100 mg, SR 200 mg) for arthritic conditions
- Flurofen – Tablets for treatment of inflammatory conditions
- Urbifen – Tablets used for anti-inflammatory and analgesic effects
- Brufen Gel – Topical gel formulation for local anti-inflammatory action
Mechanism of Action
Flurbiprofen produces its therapeutic effects primarily through the reversible inhibition of cyclooxygenase (COX), the enzyme responsible for converting arachidonic acid to prostaglandin G2 (PGG2) and subsequently to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. By inhibiting this enzyme, flurbiprofen effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling, and fever. Unlike some newer NSAIDs that selectively target COX-2, flurbiprofen is a non-selective COX inhibitor, meaning it inhibits both COX-1 and COX-2 isoforms.
The S-enantiomer appears to possess most of the anti-inflammatory activity, while both enantiomers contribute to the analgesic effects. Notably, flurbiprofen is recognized as one of the most potent NSAIDs in terms of prostaglandin inhibitory activity, which accounts for its efficacy at relatively low doses compared to some other NSAIDs.
Pharmacokinetics
Flurbiprofen demonstrates favorable pharmacokinetic properties that contribute to its clinical utility. After oral administration, it is rapidly and almost completely absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 0.5 to 4 hours.
The drug exhibits extensive plasma protein binding (greater than 99%), primarily to albumin, though it binds to a different primary binding site on albumin than anticoagulants, sulfonamides, and phenytoin, which helps explain certain interaction patterns.
The volume of distribution varies slightly among different patient populations: approximately 14 L in healthy adults, 12 L in geriatric arthritis patients, 10 L in end-stage renal disease patients, and 14 L in patients with alcoholic cirrhosis. Expressed by weight, this translates to roughly 0.12 L/kg.
Metabolism occurs primarily in the liver, with cytochrome P450 2C9 playing a crucial role in converting flurbiprofen to its major metabolite, 4′-hydroxy-flurbiprofen. This metabolite has shown little anti-inflammatory activity in animal models. The elimination half-life of flurbiprofen ranges from 4.7 to 5.7 hours. Less than 3% of the drug is excreted unchanged in urine, with approximately 70% of the dose eliminated as parent drug and metabolites via renal pathways, making renal elimination a significant route for clearance of flurbiprofen metabolites.
Therapeutic Uses
Flurbiprofen is employed in treating various conditions, with different formulations targeting specific therapeutic areas:
| Formulation | Therapeutic Uses | Dosage Forms |
|---|---|---|
| Oral | Rheumatoid arthritis | Tablets, SR tablets |
| Oral | Osteoarthritis | Tablets, SR tablets |
| Oral | Ankylosing spondylitis | Tablets, SR tablets |
| Oral | Dysmenorrhea (menstrual pain) | Tablets |
| Oral | Mild to moderate inflammatory pain (bursitis, tendonitis) | Tablets |
| Ophthalmic | Prevention of intraoperative miosis during eye surgery | Solution/drops |
| Oromucosal | Symptomatic relief of sore throat | Lozenges, spray |
| Topical | Local inflammation and pain | Gel, cream |
The oral formulations of flurbiprofen are primarily utilized for systemic effects in arthritic conditions and pain management, while specialized formulations target specific tissues like the eyes or throat.
Side Effects
Like other NSAIDs, flurbiprofen can cause a range of side effects that require monitoring. The most common adverse effects include gastrointestinal disturbances such as stomach pain, upset stomach, nausea, diarrhea, and constipation. Other frequently reported side effects include headache, fluid retention, and urinary tract infection.
More serious adverse events, though less common, warrant particular attention. These include cardiovascular thrombotic events (heart attack and stroke risk), heart failure and edema, gastrointestinal toxicity (including bleeding and ulceration), and renal toxicities. Mild elevations in liver enzymes can occur in up to 15% of patients taking flurbiprofen, though these are generally transient and asymptomatic, often resolving even with continued use of the medication.
Additional concerns include potential for anemia, hyperkalemia (elevated potassium levels), and effects on platelet aggregation that may increase bleeding risk. The risk of adverse events is typically higher in elderly patients, those with pre-existing cardiovascular or gastrointestinal conditions, and with prolonged use of high doses.
Drug Interactions
Flurbiprofen has an extensive drug interaction profile, with 402 known drug interactions documented. These include 98 major interactions, 295 moderate interactions, and 9 minor interactions. Due to its high protein binding and effects on various physiological systems, flurbiprofen can interact with numerous medications.
Significant interactions occur with other NSAIDs and aspirin, potentially increasing the risk of gastrointestinal adverse effects. Anticoagulants and antiplatelet agents can have enhanced effects when combined with flurbiprofen, increasing bleeding risk. Antihypertensive medications may have reduced efficacy when used concurrently with flurbiprofen, potentially leading to higher blood pressure.
Other important interactions include those with corticosteroids (increased gastrointestinal risk), lithium (increased lithium levels), methotrexate (increased methotrexate toxicity), cyclosporine (increased nephrotoxicity risk), and diuretics (reduced diuretic efficacy). ACE inhibitors and angiotensin II receptor blockers may have diminished effects and increased risk of kidney dysfunction when co-administered with flurbiprofen.
Safety Considerations
Several important safety considerations guide the appropriate use of flurbiprofen. The drug is contraindicated in patients with known hypersensitivity to flurbiprofen or any excipients in the formulation. Additionally, it should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, as severe, rarely fatal, anaphylactic-like reactions can occur in such patients.
Flurbiprofen is specifically contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery due to increased cardiovascular risks. The FDA has required updating drug labels for all NSAIDs, including flurbiprofen, to describe the risk of kidney problems in unborn babies resulting in low amniotic fluid. Consequently, NSAIDs are recommended to be avoided in pregnant women at 20 weeks or later in pregnancy.
Regarding lactation, flurbiprofen is poorly excreted into human milk. Due to the low levels in breastmilk and its short half-life, it is unlikely to adversely affect breastfed infants, especially if the infant is older than 2 months. Special caution should be exercised in elderly patients and those with renal or hepatic impairment, as they may be more susceptible to adverse effects.
Regulatory Status
Flurbiprofen has been approved by regulatory authorities worldwide and is available in various formulations across global markets. In the United States, the FDA approved flurbiprofen in 1988, with the first generic version receiving approval in 1994. It is classified under multiple Anatomical Therapeutic Chemical (ATC) codes, including M01AE09 (anti-inflammatory and antirheumatic products), S01BC04 (ophthalmologicals), M02AA19 (topical products for joint and muscular pain), and R02AX01 (throat preparations).
The European Medicines Agency (EMA) has also approved various flurbiprofen products, as evidenced by referrals and documentation regarding products like Flurbiprofen Geiser. In the UK, several flurbiprofen-containing products are marketed, including Froben tablets and various Strefen formulations for throat pain.
Different regulatory frameworks may apply to different formulations, with prescription requirements typically more stringent for systemic (oral) preparations compared to certain topical or throat preparations, which may be available over-the-counter in some jurisdictions.
Clinical Efficacy
Published clinical data suggest that flurbiprofen at doses of 120 to 150 mg daily demonstrates comparable effectiveness to therapeutic doses of aspirin (3 to 4 g) in rheumatoid arthritis but generally causes fewer side effects. Similarly, flurbiprofen at 150 to 300 mg appears comparable with 75 to 150 mg of indomethacin in rheumatoid arthritis and degenerative joint disease, and comparable with phenylbutazone or indomethacin in ankylosing spondylitis.
When compared with other non-steroidal agents, flurbiprofen appears to be at least as effective as naproxen, ibuprofen, or sulindac, though it generally causes more side effects than these drugs. However, as no single NSAID is universally superior for all patients requiring such therapy, flurbiprofen remains an important option in the therapeutic arsenal for arthritic and pain conditions, particularly for patients who respond poorly to or cannot tolerate other NSAIDs.
Conclusion
Flurbiprofen has maintained its place in the therapeutic landscape as a potent NSAID with versatile applications across multiple dosage forms. Its strong anti-inflammatory and analgesic properties make it valuable for treating arthritic conditions, while specialized formulations extend its utility to ophthalmologic procedures and throat pain relief.
Despite the development of newer NSAIDs with improved safety profiles, flurbiprofen continues to serve an important role in pain management and anti-inflammatory therapy. As with all medications, the benefits of flurbiprofen must be carefully weighed against potential risks, with appropriate patient selection and monitoring to optimize therapeutic outcomes while minimizing adverse effects.
